Latest Headlines

Latest Headlines

Janssen will stop making injected, oral forms of antibiotic Levaquin

Johnson & Johnson's Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of its antibiotic Levaquin.

Elderly in South often prescribed drugs with dangerous side effects

A new study says doctors in the Southern part of the U.S. are too often prescribing drugs for elderly patients that can have severe side effects and for which there are better alternatives.

J&J persuades court to toss $1.1M in Levaquin damages

Johnson & Johnson has scored a partial court victory in its long-running battle over the antibiotic Levaquin. The drugmaker has faced thousands of lawsuits claiming Levaquin caused tendon injuries--and that J&J didn't do enough to warn patients and doctors of the risk.

J&J drug sales hold their own, thanks to foreign growth

For the second quarter in a row, Johnson & Johnson posted a downward tick in revenues, hobbled by currency losses. Asset writedowns, legal-settlement set-asides, and acquisition costs dug into earnings.

J&J pharma revenues tick upward on new products, overseas sales

Johnson & Johnson's first-quarter sales may have taken a hit, but its prescription drugs business actually grew.

'Animal rule' allowed for J&J drug backed for new approval

FDA advisors have backed approval for Levaquin for a new use that the federal government had pushed for.

Jury clears J&J in another Levaquin injury case

Johnson & Johnson ($JNJ) has prevailed in its latest court fight over the antibiotic Levaquin. A New Jersey jury found J&J's Ortho-McNeil-Janssen unit wasn't liable for tendon injuries

J&J scores win in Levaquin trial

A jury in Minneapolis has decided that Johnson & Johnson isn't responsible for an 84-year-old's ruptured Achilles tendon and properly warned of the risks posed by its antibiotic Levaquin. The

J&J's Levaquin on trial for second time

Another product liability suit has hit the courts. This time it's Johnson & Johnson's Levaquin at issue, with an 84-year-old plaintiff alleging that he ruptured his Achilles tendon after taking

J&J to pay $700K on Levaquin warning

A Minnesota jury has determined that Johnson & Johnson did not properly warn patients of possible tendon damage from taking the powerful antibiotic Levaquin. John Schedin, the defendant in the